|
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium. It was founded in 1953 by Paul Janssen. In 1961 Janssen Pharmaceutica was purchased by the American corporation Johnson & Johnson, and is now part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson. Its Chairman and Managing Director is the baron Ajit Shetty. ==History== The early roots of what would become Janssen Pharmaceuticals date back to 1933. In 1933 Constant Janssen, the father of Paul Janssen, acquired the right to distribute the pharmaceutical products of Richter, a Hungarian pharmaceutical company, for Belgium, the Netherlands and Belgian Congo. On 23 October 1934, he founded the ''N.V. Produkten Richter'' in Turnhout. In 1937 Constant Janssen acquired an old factory building in the ''Statiestraat 78'' in Turnhout for his growing company, which he expanded during World War II into a four-storey building. Still a student, Paul Janssen assisted in the development of Perdolan. After the war, the name for the company products was changed to ''Eupharma'', although the company name ''Richter'' would remain until 1956. Paul Janssen founded his own research laboratory in 1953 on the third floor of the building in the ''Statiestraat'', still within the ''Richter-Eurpharma'' company of his father. In 1955, he and his team developed their first drug: Neomeritine (ambucetamide), an antispasmodic found to be particularly effective for the relief of menstrual pain. On 5 April 1956, the name of the company was changed to ''NV Laboratoria Pharmaceutica C. Janssen'' (named after Constant Janssen). On 27 April 1957, the company opened a new research facility in Beerse, but the move to Beerse would not be completed until 1971-1972. On 2 May 1958, the research department in Beerse became a separate legal entity, the ''N.V. Research Laboratorium C. Janssen''. On 24 October 1961, the company was acquired by the American corporation Johnson & Johnson. The negotiations with Johnson & Johnson were led by Frans Van den Bergh, head of the Board of Directors. On 10 February 1964, the name was changed to ''Janssen Pharmaceutica N.V.'' and the seat of the company in Turnhout was also transferred to Beerse. The company was led by Paul Janssen, Bob Stouthuysen and Frans Van Den Bergh. When, in 1971-1972 the pharmaceutical production also moved to Beerse, the move from Turnhout was completed. Between 1990 and 2004, Janssen Pharmaceuticals expanded worldwide, and the company grew in size to about 28000 employees worldwide. 4600 of these were based in Belgium. From the beginning, Janssen Pharmaceuticals emphasized as its core activity research for the development of new drugs. The research department which was established in Beerse in 1957, developed into a large research campus. In 1987, the Janssen Research Foundation (JRF) was founded which performs research into new drugs at Beerse and in other laboratories around the globe. Janssen Pharmaceuticals became the Flemish company with the largest budget for research and development. Beside the headquarters in Beerse with its research departments, pharmaceutical production and the administrative departments, Janssen Pharmaceuticals in Belgium still has offices in Berchem (Janssen-Cilag), a chemical factory in Geel, and Janssen Biotech in Olen. The Chemical Production plant in Geel, makes the active ingredients for the company’s medicines. In 1975, the first plant of a new chemical factory ''Plant I'' was established in Geel, ''Plant II'' was opened in 1977, ''Plant III in 1984, and ''Plant IV'' in 1995. In 1999 the remaining chemical production in Beerse was transferred to Geel. About 80% of its active components are manufactured here. The site in Geel also manufactures about two-thirds of the worldwide chemical production of the pharmaceutical sector of Johnson & Johnson. In 1995, the Center for Molecular Design (CMD) was founded by Paul Janssen and Paul Lewi. In 1999, clinical research and non-clinical development become a global organization within Johnson & Johnson. In 2001, part of the research activities was transferred to the United States with the reorganization of research activities in the ''Johnson & Johnson Pharmaceutical Research Development'' (JJPRD) organization. The research activities of the ''Janssen Research Foundation'' (JRF) and the ''R.W. Johnson Pharmaceutical Research Institute'' (PRI) (United States) were merged into the new global research organization. A new building for pharmaceutical development was completed in Beerse in 2001. In 2002, a new logistics and informatics centre was opened at a new site, ''Beerse 2''. In 2003 two new research buildings were constructed, the ''Discovery Research Center'' (DRC), and the ''Drug Safety Evaluation Center'' (DSEC). On 27 October 2004, the ''Paul Janssen Research Center'', for discovery research, was inaugurated. The success of Janssen Pharmaceuticals is commonly attributed to the vision of its founder, who himself was a brilliant scientist, but was also surrounded by talented and motivated employees, both scientifically and commercially. Paul Janssen created an environment which stimulated the creativity of his research workers.〔Lewi, Paul J., Successful Pharmaceutical Discovery: Paul Janssen's Concept of Drug Research, R&D Management, Vol. 37, Issue 4, pp. 355-362, September 2007〕 In March 2015, Janssen licensed Tipofarnib (a farnesyl transferase inhibitor) to Kura Oncology who will assume sole responsibility for developing and commericalisaing the anti-cancer drug.〔(【引用サイトリンク】title=GEN - News Highlights:Kura Oncology Licenses Janssen's Tipofarnib in Cancer )〕 Later in the same month the company announced that Galapagos Pharma and regained the rights to the anti-inflammatory drug candidate GLPG1690 as well as two other compounds including GLPG1205 (a first-in-class inhibitor of GPR84).〔(【引用サイトリンク】title=GEN - News Highlights:Galapagos Regains Rights to GLPG1690 from Janssen )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Janssen Pharmaceutica」の詳細全文を読む スポンサード リンク
|